AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33367742
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg Clomiphene Citrate (CC) and 450 IU HMG
Trial: 33367742
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg Clomiphene Citrate (CC) and 150 IU HMG
Trial: 37745675
Drug: Oral cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cyclophosphamide (≤2 mg/kg daily) in SLS I
Trial: 37745675
Drug: Oral mycophenolate
RxNorm normalized name: mycophenolate
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral mycophenolate mofetil (1500 mg twice daily) in SLS II
Trial: 37745675
Drug: Oral cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cyclophosphamide (≤2 mg/kg daily) in SLS II
Trial: 37745675
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment groups pooled from SLS I and SLS II
Trial: 35051151
Drug: Ozone therapy
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozone therapy (intraarticular O2-O3 mixture hip injections with ozonated autohemotherapy)
Trial: 34700600
Drug: DWI-guided dose-painting
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWI-guided dose-painting radiotherapy (DP-RT)
Trial: 32312010
Drug: HBO therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBO therapy (Group A)
Trial: 32312010
Drug: No HBO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No HBO therapy (Group B)
Trial: 34687214
Drug: Bimekizumab 320
RxNorm normalized name: bimekizumab 320 mg in 2 mL SUBCUTANEOUS INJECTION, SOLUTION [Bimzelx]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimekizumab 320 mg at weeks 0/4, followed by bimekizumab 320 mg at week 16
Trial: 34687214
Drug: Bimekizumab 320
RxNorm normalized name: bimekizumab 320 mg in 2 mL SUBCUTANEOUS INJECTION, SOLUTION [Bimzelx]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimekizumab 320 mg at weeks 0/4, followed by placebo at week 16
Trial: 33685888
Drug: Standard regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard regimen (2.4 mg/kg body weight i.v. artesunate at 0 and 12 h)
Trial: 33685888
Drug: Simplified regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simplified regimen (4 mg/kg i.v. artesunate at 0 h)
Trial: 34583525
Drug: Autologous mesenchymal
RxNorm normalized name: AUTOLOGOUS MESENCHYMAL STROMAL CELLS SECRETING NEUROTROPHIC FACTORS
DrugBank: Debamestrocel (DB17934)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous mesenchymal stem cell (MSC) treatment
Trial: 33413233
Drug: Group-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-based intervention consisting of 12 weekly sessions delivered in primary care settings and community assets.
Trial: 33902493
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (8 sessions, 1 hour each) for parents or guardians
Trial: 35908457
Drug: oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral conjugated equine estrogens (o‐CEE, n = 104)
Trial: 35908457
Drug: transdermal 17β‐estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: transdermal 17β‐estradiol (t‐E2, n = 119)
Trial: 33758944
Drug: Strawberry consumption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strawberry consumption (2 × 25 g freeze-dried strawberry powder twice daily for 4 weeks)
Trial: 36433709
Drug: Janagliflozin 25
RxNorm normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Janagliflozin 25 mg
Trial: 36433709
Drug: Janagliflozin 50
RxNorm normalized name: canagliflozin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Janagliflozin 50 mg
Trial: 36433709
Drug: Janagliflozin 25
RxNorm normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Janagliflozin 25 mg and 50 mg
Trial: 32171183
Drug: Compression garment
RxNorm normalized name: EXTREMIT-EASE Ready-To-Wear 30-50mmHg Compression Garment (Large)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compression garment (CG) worn daily for 23 hours.
Trial: 36232995
Drug: Citrate Dialysate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citrate Dialysate (1 mmol/L)
Trial: 36232995
Drug: Acetate Dialysate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetate Dialysate (4 mmol/L)
Trial: 33113783
Drug: Control drug
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control drug (10% ethanol)
Trial: 35084634
Drug: Intralesional platelet-rich
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional platelet-rich plasma (PRP) injection
Trial: 35950601
Drug: Generic (test)
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic (test) edoxaban 60-mg tablet in fasting condition
Trial: 35950601
Drug: Generic (test)
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic (test) edoxaban 60-mg tablet in fed condition
Trial: 35950601
Drug: Branded (reference)
RxNorm normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branded (reference) edoxaban 60-mg tablet in fasting condition
Trial: 35950601
Drug: Branded (reference)
RxNorm normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branded (reference) edoxaban 60-mg tablet in fed condition
Trial: 33563752
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment with FGFR and MEK inhibitors
Trial: 33563752
Drug: FGFR-specific inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FGFR-specific inhibitors (BGJ398, erdafitinib, TAS-120)
Trial: 32668456
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg albendazole
Trial: 32641091
Drug: Chloroquine phosphate
RxNorm normalized name: Chloroquine Phosphate
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine phosphate treatment for no more than 10 days
Trial: 32641091
Drug: Lopinavir/ritonavir treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir treatment for no more than 10 days
Trial: 32641091
Drug: Chloroquine phosphate
RxNorm normalized name: Chloroquine Phosphate
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine phosphate treatment
Trial: 36155062
Drug: 0.5 g%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g% MSG in drinking water
Trial: 36155062
Drug: 1.5 g%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g% MSG in drinking water
Trial: 36155062
Drug: 3.0 g%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0 g% MSG in drinking water
Trial: 36155062
Drug: 3.0 g%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0 g% MSG in drinking water (withdrawn after 4 weeks)
Trial: 32972483
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy for psychosis (CBTp) using a novel tabletised manual
Trial: 35585570
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of conbercept (IVC) 3 days before PPV
Trial: 35585570
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of conbercept (IVC) after PPV
Trial: 33128790
Drug: COPE‐TeL programme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COPE‐TeL programme (12-week intervention including comprehensive oral and physical exercises and textured lunch gatherings)
Trial: 34267185
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose vaccine
Trial: 34267185
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose vaccine
Trial: 33024237
Drug: Eplerenone (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone (25 mg/day)
Trial: 35100493
Drug: LC hair
RxNorm normalized name: cat hair extract
DrugBank: Felis catus hair (DB10499)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LC hair essence serum injection (1 ml diluted with 0.5 ml of 0.9% normal saline, once weekly for 8 weeks)
Trial: 35100493
Drug: Botulinum toxin-A
RxNorm normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Botulinum toxin-A injection (50 units)
Trial: 36042439
Drug: Early parenteral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early parenteral nutrition (PN) commenced on day 1 or day 2 of admission
Trial: 36042439
Drug: Late parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late parenteral nutrition (PN) commenced on day 6 of admission
Trial: 33960081
Drug: Saffron 100
RxNorm normalized name: SAFFRON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saffron 100 mg/day for 8 weeks
Trial: 33481863
Drug: Postpartum mothers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postpartum mothers with family monthly income <150 USD
Trial: 32948138
Drug: Lower Criteria
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower Criteria Group (fasting plasma glucose < 5.1 mmol/L, AND 1 hour < 10.0 mmol/L, AND 2 hour < 8.5 mmol/L)
Trial: 32948138
Drug: Higher Criteria
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher Criteria Group (fasting plasma glucose < 5.5 mmol/L, AND 2 hour < 9.0 mmol/L)
Trial: 35045272
Drug: Clinical expertise
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical expertise in critical care or pulmonary medicine
Trial: 39612012
Drug: Home parenteral
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home parenteral nutrition (HPN)
Trial: 34355250
Drug: ABP 980
RxNorm normalized name: ABPC
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ABP 980 (6 mg/kg) plus pertuzumab (420 mg)
Trial: 34355250
Drug: Trastuzumab RP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab RP (6 mg/kg) plus pertuzumab (420 mg)
Trial: 35306390
Drug: DAA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAA treatment with BDI-II scores ≥ 18 at baseline
Trial: 35306390
Drug: DAA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAA treatment with BDI-II scores < 18 at baseline
Trial: 32487263
Drug: Best practices
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best practices for rational use of antibiotics (Control)
Trial: 35044504
Drug: High-dose Lycium
RxNorm normalized name: Berberis lycium whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Lycium barbarum (20 g, containing 20 mg of zeaxanthin and 2 mg of lutein)
Trial: 35044504
Drug: Low-dose Lycium
RxNorm normalized name: Berberis lycium whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose Lycium barbarum (10 g, containing 10 mg of zeaxanthin and 1 mg of lutein)
Trial: 35044504
Drug: Low-dose control
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose control (1 mg of lutein)
Trial: 35044504
Drug: High-dose control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose control (2 mg of lutein)
Trial: 32202814
Drug: Supportive‐expressive (SE)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive‐expressive (SE) psychodynamic treatment
Trial: 35062752
Drug: Standard three-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard three-dose (SD) Hepatitis B vaccine
Trial: 35062752
Drug: Double three-dose
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double three-dose (DD) Hepatitis B vaccine
Trial: 34882644
Drug: Biologics treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biologics treatment
Trial: 34331755
Drug: Kaltenborn-Evjenth orthopedic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kaltenborn-Evjenth orthopedic manual therapy (KEOMT)
Trial: 35238704
Drug: Standard del
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard del Nido cardioplegia solution (SDN)
Trial: 35238704
Drug: Modified del
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified del Nido cardioplegia solution (MDN)
Trial: 32433753
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of 2g temocillin
Trial: 32433753
Drug: Subcutaneous administration
RxNorm normalized name: subcutaneous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of 2g temocillin
Trial: 32090996
Drug: 3D laser
RxNorm normalized name: aminosalicylic acid
DrugBank: Aminosalicylic acid (DB00233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3D laser scanner (3DLS) and tablet computer for digitally assisted BCRL assessment
Trial: 34566523
Drug: Ezetimibe 10
RxNorm normalized name: ezetimibe 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe 10 mg/day plus rosuvastatin 20 mg/day (combination group)
Trial: 34566523
Drug: Rosuvastatin 20
RxNorm normalized name: rosuvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 20 mg/day (rosuvastatin group)
Trial: 35753872
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy (active)
Trial: 34310400
Drug: 10 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 μg V-01 (two-dose regimen)
Trial: 34310400
Drug: 25 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 μg V-01 (two-dose regimen)
Trial: 34310400
Drug: 50 μg
RxNorm normalized name: penicillin G 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 μg V-01 (one-dose regimen)
Trial: 34310400
Drug: Placebo (two-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (two-dose regimen)
Trial: 34310400
Drug: Placebo (one-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (one-dose regimen)
Trial: 32769506
Drug: Fluid intake
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid intake group (allowed to drink up to 400 ml of apple juice for 90 minutes after randomisation)
Trial: 32660769
Drug: Reference Pegfilgrastim
RxNorm normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Reference Pegfilgrastim (Neulasta) (6 mg/0.6 mL)
Trial: 34498320
Drug: Adapted soccer
RxNorm normalized name: ADAPT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapted soccer programme (twice a week for 16 weeks)
Trial: 34498320
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (usual daily regime)
Trial: 33962594
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: One additional dose of 1g IV‐TXA 3 hours postoperatively
Trial: 33962594
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: Three doses of 1g IV‐TXA at 3, 6, and 12 hours postoperatively
Trial: 36910518
Drug: Early discontinuation
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early discontinuation of dual antiplatelet therapy (DAPT)
Trial: 36067589
Drug: 28 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 28 g/d of dry roasted, unsalted peanuts for 6 weeks
Trial: 33829580
Drug: Anti-PD-1/PD-L1 inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-PD-1/PD-L1 inhibitors (nivolumab, pembrolizumab, or atezolizumab)
Trial: 32878758
Drug: Preoperative endoscopic
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative endoscopic injection of botulinum toxin (BTX) into the sphincter of Oddi
Trial: 34820909
Drug: 550 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 550 mg/d supplemental choline (as choline chloride)
Trial: 34820909
Drug: 25 mg/d
RxNorm normalized name: fluoride 0.25 mg/drop oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg/d d9-choline (control)
Trial: 34630560
Drug: Associated Mirror
RxNorm normalized name: HEPATITIS ASSOCIATED ANTIBODY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Associated Mirror Therapy (AMT)
Trial: 32461554
Drug: Colchicine 0.6
RxNorm normalized name: colchicine 0.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine 0.6 mg twice-daily for 3 months
Trial: 33090614
Drug: Resistance to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistance to amoxicillin
Trial: 34147151
Drug: Upadacitinib in
RxNorm normalized name: Product containing upadacitinib in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upadacitinib in combination with topical corticosteroids
Trial: 33560659
Drug: Ketamine (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.25 mg·kg‐1 bolus followed by 5 µg·kg‐1·min‐1 infusion for up to 45 minutes)
Trial: 32848185
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron supplementation (800 mg iron-carboxymaltose)
Trial: 33337237
Drug: P. foliicola
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P. foliicola spore suspension (1.0 × 10^6/ml) applied to three-week-old seedlings of mung bean cultivar 'Jilv 7' (n=5)
Trial: 33236939
Drug: Transcatheter mitral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcatheter mitral valve repair (TMVr) plus guideline directed medical therapy (GDMT)
Trial: 33236939
Drug: Guideline directed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline directed medical therapy (GDMT) alone
Trial: 39773831
Drug: Rivaroxaban (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (15 mg once daily)
Trial: 35292423
Drug: Rivaroxaban and
RxNorm normalized name: rivaroxaban and acetylsalicylic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban and Aspirin (both groups)
Trial: 35674919
Drug: Prenatal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenatal morphine treatment (twice daily, s.c. from gestational days 11–18)
Trial: 32125709
Drug: optimal standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: optimal standard therapy (control group)
Trial: 34269426
Drug: Viloxazine ER
RxNorm normalized name: viloxazine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viloxazine ER 100 mg
Trial: 34269426
Drug: Viloxazine ER
RxNorm normalized name: viloxazine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viloxazine ER 200 mg
Trial: 34269426
Drug: Viloxazine ER
RxNorm normalized name: viloxazine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viloxazine ER 400 mg
Trial: 34269426
Drug: Viloxazine ER
RxNorm normalized name: viloxazine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viloxazine ER 200 mg (adolescents)
Trial: 34269426
Drug: Viloxazine ER
RxNorm normalized name: viloxazine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viloxazine ER 400 mg (adolescents)
Trial: 34269426
Drug: Viloxazine ER
RxNorm normalized name: viloxazine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viloxazine ER 600 mg (adolescents)
Trial: 34269426
Drug: Missed doses
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Missed doses of viloxazine ER
Trial: 32448254
Drug: High treatment
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High treatment expectations at baseline
Trial: 35511322
Drug: Pelvic floor
RxNorm normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic floor physical therapy including electromyographic biofeedback for 8 weeks
Trial: 34246277
Drug: Inpatient statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient statin use (Atorvastatin was the most commonly prescribed, n = 205, 82%)
Trial: 34813125
Drug: HTK-N solution
RxNorm normalized name: N-ethylurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTK-N solution
Trial: 35906457
Drug: Daily sleep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily sleep quality
Trial: 37016357
Drug: Daily sleep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily sleep duration
Trial: 35298282
Drug: Intense Pulsed
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intense Pulsed Light (IPL) treatment, 2 treatments spaced 3 weeks apart